EVALUATION OF ANTI-TUBERCULOSIS INDUCED ADVERSE REACTIONS IN PATIENTS OF BALOCHISTAN, PAKISTAN by Uzma Bashir, Marvi Baloch, Javeid Iqbal, Sajjad Haider, Fahad Saleem
IAJPS 2017, 4 (03), 740-746                                  Fahad Saleem et al                            ISSN 2349-7750 
 
 w w w . i a j p s . c o m  
 
Page 740 
                                                                        
  CODEN (USA): IAJPBB                             ISSN: 2349-7750 
INDO AMERICAN JOURNAL OF             
PHARMACEUTICAL SCIENCES 
               
Available online at: http://www.iajps.com                                      Research Article 
EVALUATION OF ANTI-TUBERCULOSIS INDUCED 
ADVERSE REACTIONS IN PATIENTS OF BALOCHISTAN, 
PAKISTAN 
Uzma Bashir, Marvi Baloch, Javeid Iqbal, Sajjad Haider, Fahad Saleem 
Faculty of Pharmacy & Health Sciences, University of Balochistan, Quetta, Pakistan 
Abstract: 
Objective:  
Pakistan is ranked 5th in the world in terms of having immense Tuberculosis (TB) burden. During the course of TB treatment, 
adverse drug reactions (ADRs) due to anti-TB drugs are a killer problem. Therefore, the present study was conducted on 200 TB 
patients to explore the incidence of ADRs due to anti-TB drugs.   
Methods: 
This is a multicenter study conducted at two public healthcare institutes of Quetta city, Pakistan. Data of 200 patients was 
screened from the official records and evaluated to identify variables of interest. All necessary diagnostic tests were performed 
before starting the therapy and after every 2 months during the study. Data was collected through a validated information sheet. 
Descriptive SPSS v.20 was used for data analysis.  
Results: 
A total of 200 patients were enrolled in the study. In this study, most frequently reported ADR was fever (163, 84.5%) followed by 
nausea (152, 76%) and epigastric pain (117, 58.5%). Interestingly, the most commonly reported ADR in literature (constipation 
and weight gain) were least reported in the current study. Thirty nine (19.5%) patients were admitted to hospital during the study 
because of the observed ADRs. During the study, 46 (23%) patients were given re-challenge to ADRs and were managed by 
giving additional medicines with TB drug treatment regimen. One hundred and eighty three I(91.5%) patients from both 
hospitals were given a complete 6 months therapy. However, 5 (2.5%) patients died during the therapy and 12 (6%) patients 
underwent therapy discontinuation because of unidentified reasons. 
Conclusion: 
Majority of the patients experienced ADRs and the management of most ARDs was done by therapy modifications. It was also 
observed during the study that some patients did not report common and clinically mild ADRs, so it is the duty of health 
practitioners to interrogate and investigate the patients keenly. Health practitioner should also take immediate actions to combat 
the ADRs and improve the patient’s quality of life. 
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Tuberculosis (TB) is one of the major causes of 
mortality worldwide, resulting in death of more than 2 
million patients annually. The World Health 
Organization (WHO) has reported that one third 
population of the world is infected with the disease and 
90% of them are from developing countries[1,2]. Hence, 
TB is a killing disease for less developed and low 
revenue countries [3]. Within this context, a total of six 
Asian countries namely Pakistan, China, India, 
Bangladesh, Philippines and Indonesia were reported 
with the highest incidence rates of TB [4].  
Inline to what is reported, Pakistan is among top 22 
underdeveloped countries affected by the disease [5] 
and is ranked 5th in the world in having the disease 
burden, with approximately 47% cases of pulmonary TB 
(PTB) [6] . Additionally, there is increased risk of 
developing TB among individuals with family history of 
the disease and the workers of health care settings[7,8]. 
Other risk factors for the disease are younger age, 
gender, socioeconomic status (SES), lack of awareness 
and various other diseases [9 ,10].  
During the treatment of TB, the goals are cure without 
recurrence, prevention of transmission and improved 
patient survival. Combination treatment for the period of 
6-8 months is the current treatment of TB. The treatment 
is usually completed in two phases: initial phase and 
continuous phase[11]. The 1st line anti-TB drugs are 
based on mode of action and are isoniazid (INH), 
ethambutol (EMB), rifampicin/rifampin (RIF), 
pyrazinamide (PZA) and rifapentine or rifabutin. For the 
period of first two months, patients receive 3-4 drugs 
(RIF, INH, PZA and EMB). During next 4 months they 
are continued with INH and RIF only. However, Anti-
TB drugs can cause frequent and severe ADRs [12]. 
Different studies have reported that >5% patients on 
anti-TB drugs develop ADRs. The most common of 
them are hepatotoxicity and skin reactions [13]. These 
ADRs can do immense harm to the patients and may 
need different examination tests and treatments[14]. 
Such ADRs may lead to prolonged hospitalization and 
even death of the patient. Detection of such ADRs is a 
key to monitor drug safety as it motivates the edification 
of health authorities concerning potential ADRs. 
Therefore the current study was aimed to explore the 
incidence of ADRs due to anti-TB drugs attending 
public hospitals of Quetta, Pakistan.  
 
METHODS: 
Research, settings and time frame 
The present descriptive questionnaire based 
observational study was conducted on both hospitalized 
patients and those attending the outdoor TB clinics of 
two hospitals i.e. Fatima Jinnah Chest and General 
(FJGC) Hospital and Bolan Medical Complex (BMC) 
Hospital, Quetta, Balochistan. The study was carried out 
for the period of 6 months.  
Ethical approval, data collection & variables of the 
study 
Institutional Review Committee of Faculty of Pharmacy 
& Health Sciences, University of Balochistan approved 
the study. In addition, permissions for the study were 
obtained from the concerned medical superintendents 
and an informed consent was signed by the patients 
before the beginning of the study. The patients were 
informed about the purpose of the study and were 
counseled regarding the disease, treatment and possible 
adverse effects. Re-counseling was performed when 
necessary. A structured data collection sheet was used 
for data collection.  
Before starting anti TB therapy the recruited participants 
completed a questionnaire and received different 
laboratory examinations, including routine blood and 
urine tests, serological tests for hepatitis B surface 
antigen (HBsAg) and anti-hepatitis C antibody (anti-
HCV), liver function test (LFT) and renal function test 
(RFT). During the follow up period, all examinations 
were measured after every 2 months during the 
treatment. The participants were also instructed to self-
record any ADR by using a diary and to report them to 
the researcher/doctor. Once a suspected ADR was 
identified, it was followed up until resolution or 
completion of therapy. The participants of study visited 
the doctor/researcher once weekly and presented their 
data to doctor/researcher until the completion of 
therapy. Detection and monitoring was done by 
interviewing patients and reviewing laboratory tests. 
Sampling 
The study was conducted on 200 patients (n=200) 
suffering from pulmonary TB (PTB) after fulfilling 
inclusion and exclusion criteria irrespective of age, sex, 
and race.  
Inclusion criteria 
The patients of any age and gender, suffering from PTB, 
not enrolled in any TB support or educational program 
were targeted for the study. Patients with hyper-
vitaminosis, not able to visit the hospital regularly, 
receiving other treatment regimens, compromised or 
having MDR (Multi Drug Resistance) TB were 
excluded from the study. Both hospitalized patients and 
the patients from outdoor TB clinics of the hospitals 
were enrolled in the study after fulfilling the inclusion 
and exclusion criteria.   
Statistical analysis 
Statistical analysis was performed with statistical 
package for social sciences (SPSS) software version 
20.0. Descriptive statistics were used to describe 
demographic and disease characteristics of the patients. 
Percentages and frequencies were used for the 
categorical variables, while means and standard 
deviations were calculated for the continuous variables. 
The characteristics of the whole sample were presented. 
 
RESULTS: 
Two hundred patients attended the survey. One hundred 
and forty two (71%) were ranked as out-patients while 
the rest were admitted to the hospital. The cohort was 
dominated by males (123, 61.5%) and majority was in 
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the age range of 20-29 years (62, 31.0%). One hundred 
and forty one were married (141, 70.5%) and belonging 
to the middle class (111, 55.5%) as shown in Table 1. 
 
Table 1: Demographic characteristics of the patients 
Characteristics Frequency Percentage 
Age (years) 7 3.5 
<10 30 15.0 
10-19 54 27.0 
20-29 62 31.0 
30-39 25 12.5 
40-49 11 5.5 
50-59 7 3.5 
60-69 4 2.0 
> 70 7 3.5 
Gender   
Male 123 61.5 
Female 77 38.5 
Status   
Single 34 17.0 
Married 141 70.5 
Divorced 18 9.0 
Widowed 7 3.5 
Body Mass Index   
Underweight 17 8.5 
Normal weight 85 42.5 
Overweight 91 45.5 
Obesity 7 3.5 
Socio-economic status   
Lower (< 10,000 Pk. Rs per month) 89 44.5 
Middle (10,000-30,000 Pk. Rs per month) 111 55.5 
Educational status   
Not going to school 11 5.5 
Illiterate 119 59.5 
Primary 37 18.5 
Middle 16 8.0 
Matric 16 8.0 
Bachelor 1 0.5 
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Table 2 provides the data on the incidence of ADR 
among the patients. In this study, most frequently 
reported ADR was fever (163, 84.5%) followed by 
nausea (152, 76%) and epigastric pain (117, 58.5%). 
Interestingly, the most commonly reported ADR in 
literature (constipation and weight gain) were least 
reported in the current study. An important observation 
of the study was that the incidence of ADR was almost 
equal to both hospitals. 
In FJGC hearing loss was observed in 24, vertiligo in 
33, new-onset tinnitus in 18, itching in 28, hives in 8, 
fever in 77, petechial rash in 4, anorexia in 42, nausea in 
80, vomiting in 56, epigastric pain in 59, diarrhoea in 
31, constipation in 3, yellow coloration of eyes 
(jaundice) in 32, hepatitis in 3,  fatigue in 75, weight 
gain in 2, sluggish reflexes in 6, depression in 42, gout-
like manifestations in 5, joint pain in 46, headaches in 
60, agitation in 37, suicidal ideation in 15, numbness or 
paresthesias of feet or hands in 17, urine discoloration in 
16, hematuria in 5, azotemia in 5, vision loss in 7, 
colour blindness in 6, uveitis in 4, rashes with itching in 
55, rashes without itching in 25, urticaria in 18, 
angioedema in 6 and skin eruption in 9 patients.  
In BMC hearing loss was observed in 18, vertiligo in 26, 
new-onset tinnitus in 23, itching in 11, hives in 17, fever 
in 86, petechial rash in 9, anorexia in 35, nausea in 72, 
vomiting in 40, epigastric pain in 58, diarrhoea in 28, 
yellow coloration of eyes (jaundice) in 28, hepatitis in 5,  
fatigue in 77, weight gain in 1, sluggish reflexes in 18, 
depression in 32, gout-like manifestations in 10, joint 
pain in 48, headaches in 34, agitation in 41, suicidal 
ideation in 15, numbness or paresthesias of feet or hands 
in 15, urine discoloration in 14, hematuria in 18, 
azotemia in 16, vision loss in 7, colour blindness in 5, 
uveitis in 6, rashes with itching in 57, rashes without 
itching in 29, urticaria in 10, angioedema in 9 and skin 
eruptionin 8 patients, as represented in Table 2. 
Table 2: Incidence of ADR development in two hospitals 
ADR FJGC* BMC* 
Hearing loss 24 18 
Vertigo 33 26 
New-onset tinnitus 18 23 
Itching 28 11 
Hives 8 17 
Fever 77 86 
Petechial rash 4 9 
Anorexia 42 35 
Nausea 80 72 
Vomiting 56 40 
Epigastric pain 59 58 
Diarrhoea 31 28 
Constipation 3 0 
Jaundice 32 28 
Hepatitis 3 5 
Fatigue 75 77 
Weight gain 2 1 
Sluggish reflexes 6 18 
Depression 42 32 
Gout like manifestations 5 10 
Joint pain 46 48 
Headache 60 34 
Agitation 37 41 
Suicidal ideation 15 15 
Numbness or paresthesias of feet or hands 17 15 
Urine discoloration 16 14 
Hematuria 5 18 
Azotemia 5 16 
Vision loss 7 7 
Color blindness 6 5 
Uveitis 4 6 
Rashes with itching 55 57 
Rashes without itching 25 29 
Urticaria 18 10 
Angioedema 6 9 
Skin eruption 9 8 
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*number of patients  
A total of 39 (19.5%) patients were admitted to hospital during the study for the observed ADRs. However, 44 (22 
%) patients were already admitted to hospital for TB treatment purpose. A total of 46 (23%) patients were given re-
challenge to ADRs and conversely, 154 (77%) patients were managed by giving additional medicines with TB drug 
treatment regimen (Table 3).  
 
Table 3: Frequency distribution patients admitted to hospital and re-challenged for ADRs 
Admitted to Hospital Frequency Percent 
Yes 39 19.5 
No 117 58.5 
Already hospitalized 44 22.0 
Re-challenge to patients on ADR   
Yes 46 23.0 
No (ADRs managed with additional drugs) 154 77.0 
Table 4: Frequency distribution of other diagnosed diseases during TB treatment 
Disease Frequency Percent 
No disease 176 88.0 
Gout 9 4.5 
Hepatitis 3 1.5 
Hepatitis and Impaired Renal Functions 3 1.5 
Hepatitis and Renal Failure 2 1.0 
Impaired Renal Functions 5 2.5 
Impaired Renal Functions and Impaired Liver Function 1 0.5 
Piles (already) 1 0.5 
 
During the study it was observed that 1 (0.5%) patient 
was already suffering from piles. During the disease 
treatment (9, 4.5%) developed gout, 3 (1.5%) developed 
drug induced hepatitis, 3 (1.5%) developed drug 
induced hepatitis along with impaired renal function, 2 
(1%) developed drug induced hepatitis and renal failure, 
5 (2.5%) developed impaired renal function and 1 
(0.5%) patient developed both impaired renal and 
impaired liver functions. However, 176 (88%) patients 
did not develop any other disease as shown in Table 4. 
In the study, 183 (91.5%) patients from both hospitals 
were given a complete 6 months therapy. However, 5 
(2.5%) patients died during therapy and 12 (6%) 
patients underwent therapy discontinuation results were 
shown in table 4.  
 
DISCUSSION & CONCLUSION: 
Among 200 patients all experienced ADRs, which was 
significantly a large number. Management of most 
ARDs was done by therapy modifications and by adding 
certain medicines. It was observed during the study that 
some patients often did not report common and 
clinically mild ADRs, so it is the duty of health 
practitioner and researcher to interrogate and investigate 
the patients keenly. Health practitioner should also take 
immediate actions to combat the ADRs and improve the 
patient’s quality of life. 
Pulmonary tuberculosis (PTB) is a complex disease to 
treat and ADRs to anti-TB drugs are a rising problem 
worldwide. As the disease treatment involves use of 
drugs in combination for a lengthened time period, there 
is high incidence of ADRs. Additionally, the ADR of 
one drug may possibly be augmented by associated 
drug, which may be a major cause for the false patient 
treatment. Demographic factors including gender, age, 
TB history in family, smoking history, socio-economic 
status (SES) and education, affect a person’s health 
condition. Javadi et al., (2007)[15] conducted a study on 
204 hospitalized patients receiving 1st line anti-TB 
drugs. The study was aimed to evaluate the frequencies 
of ADRs. A total of 92 patients were presented with 
ADRs in the study. The ADRs were more frequently 
reported by patients with TB history in family. However 
in our study all 200 (100%) patients reported the ADRs 
and 117 (58.5%) patients were having TB history in 
family. Frequency of TB patients with family history of 
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the disease was more than those without TB history in 
their families. 
Tariq et al. (2010)[16]  carried out a study 500 outdoor 
patients suffering from PTB and extra PTB (EPTB). The 
study revealed that the disease was more common in 
early adulthood and adolescence.  However the present 
study was carried out on 200 patients both outdoor and 
hospitalized. Among them 58 (29%) patients were 
hospitalized for the disease and 142 (71%) were outdoor 
TB patients. A total of 39 (19.5%) patients were 
admitted to hospital during the study for the observed 
ADRs. Additionally, Tariq et al. (2010) [16] supported 
our results of age. Similarly, to their study, our 
investigations also revealed that the disease was 
common in the age of 20-39 years and even, more 
common in the age range of 30-39 years. 
Khan et al. (2013) [17] carried out a retrospective study 
to assess the incidence of TB in the hospital of Penang, 
Malaysia on 1548 patients. In the study, 77.5% TB 
patients were male and 22.5% patients were female. 
Concluding, in their study the disease was found more 
prevalent in males[17]. In our study, a total of 123 
(61.5%) males and 77 (38.5%) females fulfilling the 
inclusion criteria were enrolled. The male TB patients 
were more in number in our study like the study 
conducted by Kurniawati et al., (2012) [18] and Khan et 
al., (2013) [17].  
Amin et al., (2014) [19] performed a study to determine 
the risk factors for TB on 164 patients for the period of 
6 months. It revealed that TB was more common in 
patients with low SES, illiterate or less educated people, 
males and those with family history of the disease [19]. 
Gopi et al., 2007 [20] also reported that illiteracy (71%) 
was exceedingly prevalent among TB patients [20] 
(Gopi et al., 2007). Similarly, our study was carried out 
for the period of 6 months revealing that the disease was 
more common in illiterate people (n = 119, 59.5%), the 
diseases was found more common in males (n=123, 
61.5%) and in patients of  middle class (earning 10,000-
30,000 Rs per month). 
Drug hepatotoxicity, hyperglycemia, headache, 
peripheral neuropathy, dysuria, increased uric acid, 
tingling sensation of feet and hands, Joint pain, 
generalized itching, skin rashes, anorexia, nausea, 
headache, vomiting, tinnitus [21,22], fever, 
hyperbilirubinemia, porphyria, constipation, diarrhea, 
cough, red blood cells (RBC) and white blood cells 
(WBC) disturbances, thrombocytopenia and dim vision 
are commonly reported ADRs of anti-TB drugs 
[14,23,24].  All these ADRs were also reported in our 
study. 
RIF, EMB and INH are the common drugs causing 
headache. Agitation, blurred vision or decrease in 
visual, uveitis, depression and suicidal ideation are other 
ADRs of INH. These ADRs are dose dependent. The 
symptoms can be improved by administrating other 
medicines. In our study, headache was reported in 94 
(47%) patients, agitation in 78 (39%) patients, vision 
impairment in 14 (7%), uveitisin only 10 (5%) patients, 
depression in 74 (37%) patients and suicidal ideation in 
30 (15%) patients. 
Damasceno et al. (2013) [24] conducted a descriptive 
study in Manguinhos, Rio de Janeiro, Brazil, by 
reviewing the record of TB patients from 2004-2008. 
The study was designed to characterize and evaluate the 
frequency of ADRs to anti-TB drugs. RBC and WBC 
disturbances were observed in the study [24]. Similarly, 
in our study RBC count was below normal in 37 
(18.5%) patients and WBC count was below normal in 
17 (8.5%) patients. However, it was above normal in 7 
(3.5%) patients.  
Limitations 
The limited sample size is an issue while discussing 
about the generalizability of the results. 
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The authors have no conflict of interest to declare. No 
funding was received for this study. 
REFERENCES: 
1. Cegielski, J. P., Chin, D. P., Espinal, M. A., Frieden, 
T. R., Rodriquez Cruz, R., & Talbot, E. A. The global 
tuberculosis situation. Progress and problems in the 20th 
century, prospects for the 21st century. Infect Dis Clin 
North Am,2002: 16(1): 1–58. 
2. Metcalf, E. P., Davies, J. C., Wood, F., &Butler, C. C. 
Unwrapping the diagnosis of tuberculosis in primary 
care, a qualitative study. Br J Gen Pract, 2007;57 
(535):116–22. 
3. Haque, A. F., Arif-uz-Zaman, K., Begum, L., Israt, J. 
M., Tasmia, I., Shovon, C., Mohammad, A. R. B., & 
Niajur, R.  Assessment of Bangladeshi mothers’ 
knowledge and awareness on childhood tuberculosis, A 
cross sectional study. Science Journal of Public Health, 
2014;2(4): 309-315. 
4. Sandhu, G. K. Tuberculosis, current situation, 
challenges and overview of its control programs in 
India. J Glob Infect Dis, 2011;3(2): 143–150. 
5. Akhtar, S., White, F., Hasan, R., Rozi, S., Younus, 
M., & Ahmed, F. Hyperendemic pulmonary tuberculosis 
in peri-urban areas of Karachi, Pakistan. BMC Public 
Health,2007;3(7): 70. 
6. Naseer, M., Khawaja, A., Pethani, A. S., & Aleem, S.  
How well can physicians manage Tuberculosis? A 
Public-Private sector comparison from Karachi, 
Pakistan. BMC Health Serv Res,2013; 13(1): 439. 
7. Jonsson, J., Kan, B., Berggren, I., & Bruchfeld, 
J.Extensive nosocomial transmission of tuberculosis in a 
IAJPS 2017, 4 (03), 740-746                                  Fahad Saleem et al                            ISSN 2349-7750 
 
 w w w . i a j p s . c o m  
 
Page 746 
low-incidence country. J Hosp Infect, 2013;83(4): 321–
326. 
8. Stevens, H., Ricardo, A. X., Odimariles, M. D., & 
Laura, C. R. Risk factors for tuberculosis in older 
children and adolescents, a matched case–control study 
in Recife, Brazil. Emerg Themes Epidemiol,2014; 
11(20): 7. 
9. Yang, Z., Kong, Y., Wilson, F., Foxman, B., Fowler, 
A. H., Marrs, C. F., Cave, M.D., & Bates, J. 
H.Identification of risk factors for extrapulmonary 
tuberculosis. Clin Infect Dis,2004; 38(2): 199-205. 
10. Fiske, C. T., Griffin, M. R., Erin, H., Warkentin, J., 
& Lisa, K. (2010). Black race, sex, and extrapulmonary 
tuberculosis risk, an observational study. BMC Infect 
Dis. DOI: 10.1186/1471-2334-10-16 
11. Lounis, N., Maslo, C., Truffot-Pernot, C., Grosset, 
J., & Boelaert, R. J. Impact of iron loading on the 
activity of isoniazid or ethambutol in the treatment of 
murine tuberculosis. Int J Tuberc Lung Dis,2003; 7(6): 
575-579. 
12. Gholami, K., Kamali, E., Hajiabdolbaghi, M., & 
Shalviri, G. Evaluation of anti-tuberculosis induced 
adverse reactions in hospitalized patients. Pharm 
Pract,2006; 4(3): 134-138. 
13. Dassanayake, D. L. B., Asanga, B. K. M., 
Wickramasekara, K.,Ileperuma, S. K., Siribaddana, A., 
& Wijewardena, K. A. Association of food and drug 
allergy with antituberculosis drug related hepatitis or 
skin reactions. A case control study. J Tuber Lung 
Dis2013;, 10(2): 48-53. 
14. Xia, Y. Y., Hu, D. Y., Liu, F. Y., Wang, X. M., 
Yuan, Y. L., Tu de, H., Chen, Y. X., Zhou, L., Zhu, L. 
Z., Gao, W. W., Wang, H. Y., Chen da, F., Yang, L., 
He, P.P., Li, X.T., He, Y. J., Sun, F., & Zhan, S. Y. 
Design of the anti-tuberculosis drugs induced adverse 
reactions in China. BMC Public Health,2010; 10, 267. 
15. Javadi, M. R., Shalviri, G., Gholami, K., 
Salamzadeh, J., Maghooli, G., & Mirsaeedi, S. M. 
Adverse reactions of anti-tuberculosis drugs in 
hospitalized patients, incidence, severity and risk 
factors. Pharmacoepidemiol Drug Saf, 2007;16(10): 
1104-1110. 
16. Tariq, S.,Rauf, A., Malik, S. & Rashid, A. 
Presentations of tuberculosis in northern Pakistan. 
Journal of Ayub Medical College Abbottabad,2010; 
23(1), 40-42. 
17.Khan, A. H., Sulaiman, S. A. S., Muttalif, A. R., 
Hassali, M. A., Akram, H., & Gillani, S. W. Pleural 
tuberculosis and its treatment outcomes. Trop J Pharm 
Res, 2013;12(4); 623-627. 
18. Kurniawati, F., Sulaiman, S. A. S., & Gillani, S. W.. 
Adverse drug reactions of primary anti-tuberculosis 
drugs among tuberculosis patients treated in chest clinic. 
IJPLS,2012; 3(1): 1331-1338. 
19. Amin, M., AmanUllah, M., Ajmal, M, & Tabasum, 
S. TB category, associated factors in Multan. 
Professional Med J, 2014;21(4) :659-666. 
20. Gopi, P. G., Vasantha, M., Muniyandi, M., 
Chandrasekaran, V., Balasubramanian, R., & 
Narayanan, P. R. Risk factors for non-adherence to 
directly observed treatment (DOT) in a rural 
tuberculosis unit. Indian J Tuberc, 2007;54: 66-70. 
21. Chhetri, A. K., Saha, A., Verma, S. C., Palaian, S., 
Mishra, P., & Shankar, P. R. A study of adverse drug 
reactions caused by first line anti-tubercular drugs used 
in Directly Observed Treatment, Short course (DOTS) 
therapy in western Nepal, Pokhara. J Pak Med Assoc, 
2008;58: 531-536. 
22.Khalil, H., Dashti-Khavidaki, S., Rasoolinejad, M., 
Rezaie, L., & Etminani, M. Anti-tuberculosis drugs 
related hepatotoxicity, incidence, risk factors, pattern of 
changes in liver enzymes and outcome. DARU,2009; 
17(3): 163-23.Rajanandh, M. M., Nageswari, A. D., 
Ramasamy, C., & Dinesh, V. Side Effects of 
Antitubercular drugs on directly observed treatment 
strategy under revised national tuberculosis control 
programme in a teaching hospital. Global Journal of 
Pharmacology, 2012;6(1): 29-32. 
24. Glauciene Santana Damasceno, Lusiele Guaraldo, 
Elyne Montenegro Engstrom, Mariza Miranda Theme 
Filha, Reinaldo Souza-Santos, Ana Gloria Godoi 
Vasconcelos, Suely Rozenfeld, Adverse reactions to 
antituberculosis drugs in Manguinhos, Rio de Janeiro, 
Brazil, CLINICS 2013;68(3):329-337. 
 
 
 
 
 
